19 completed, 13 terminated, 5 active not recruiting, 1 recruiting. 40 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 40 | Completed 19, Terminated 13, Active not recruiting 5, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 11 | Terminated 4, Active not recruiting 3, Completed 3, Recruiting 1 |
Follow LEE011: new trials by email Literature Review of LEE011 trials Research Report on LEE011
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors Topotecan, Temozolomide, Ribociclib - Neuroblastoma | Phase 1 | Terminated | Novartis Pharmaceuticals | 12 | 2022-12-27 | 2025-10-10 |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation JDQ443, trametinib, Ribociclib - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 74 | 2022-10-24 | 2026-10-21 |
| Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer Carboplatin, Docetaxel, Fulvestrant - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 18 | 2022-04-07 | 2026-05-11 |
| Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases Abemaciclib, Palbociclib, Quality-of-Life Assessment - Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma | Phase 1 | Withdrawn | Emory University | 2020-06-12 | 2021-10-18 | |
| Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies TNO155, Spartalizumab, Ribociclib - Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma | Phase 1 | Terminated | Novartis Pharmaceuticals | 122 | 2019-07-30 | 2025-09-30 |
| Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL Ribociclib, Dexamethasone, Everolimus - Acute Lymphoblastic Leukemia ALL | Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 45 | 2019-01-30 | 2026-08-21 |
| Ribociclib and Bicalutamide in AR+ TNBC ribociclib, Bicalutamide - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Kari Wisinski | 37 | 2018-05-07 | 2026-01-02 |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Gemcitabine, ribociclib, sonidegib - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | St. Jude Children's Research Hospital | 68 | 2018-03-05 | 2024-05-31 |
| Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors Everolimus, Laboratory Biomarker Analysis, Pharmacological Study - CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 22 | 2018-01-13 | 2021-08-27 |
| Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Completed | Mayo Clinic | 43 | 2018-01-04 | 2023-01-05 |
| Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer Ribociclib, PDR001, Fulvestrant - Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer | Phase 1 | Terminated | Dana-Farber Cancer Institute | 33 | 2017-11-08 | 2025-05-31 |
| LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy LEE011, Everolimus - Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Completed | Georgetown University | 12 | 2017-05-04 | 2026-04-07 |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 16 | 2017-03-10 | 2023-08-16 |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Ribociclib, Topotecan, Temozolomide - Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 472 | 2016-08-03 | 2026-07-10 |
| Next Generation Personalized Neuroblastoma Therapy Biopsy, Next Generation Sequencing, Tumor Scans - Neuroblastoma, Cancer | Phase 1 | Terminated | Yael P Mosse | 66 | 2016-07-01 | 2026-03-10 |
| Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors ribociclib, Trametinib - Solid Tumors for Phase Ib, Pancreatic Cancer for Phase II | Phase 1 | Terminated | Novartis Pharmaceuticals | 95 | 2016-06-29 | 2020-12-21 |
| Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers LSZ102, LEE011, BYL719 - Advanced or Metastatic ER+ Breast Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 199 | 2016-06-14 | 2022-08-01 |
| A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy Ribociclib - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Terminated | Children's Hospital Medical Center, Cincinnati | 11 | 2016-04-01 | 2020-11-05 |
| Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma Ribociclib - Glioblastoma, Glioma | Phase 1 | Unknown | University of Virginia | 3 | 2016-03-01 | 2018-06-07 |
| TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer Tamoxifen, Ribociclib, Goserelin - Breast Cancer, Breast Cancer - Female | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 7 | 2016-02-23 | 2022-01-21 |
Showing 20 of 40. Sign in to see all of them.
Breast Neoplasms (8) · Glioma (5) · Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Medulloblastoma (3) · Neoplasm Metastasis (3) · Neuroblastoma (3) · Recurrence (3) · Brain Neoplasms (2) · Diffuse Intrinsic Pontine Glioma (2) · Glioblastoma (2) · Liposarcoma (2) · Lymphoma (2) · Rhabdoid Tumor (2)
Novartis Pharmaceuticals (18) · Dana-Farber Cancer Institute (2) · Pfizer (2) · Array BioPharma (1) · Children's Hospital Medical Center, Cincinnati (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Emory University (1) · Georgetown University (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jonsson Comprehensive Cancer Center (1) · Kari Wisinski (1) · Mayo Clinic (1) · OHSU Knight Cancer Institute (1) · Pediatric Brain Tumor Consortium (1)
United States (33) · France (12) · Spain (11) · Germany (10) · Italy (10) · Australia (8) · Singapore (8) · Belgium (7) · Netherlands (6) · United Kingdom (6) · Canada (5) · Japan (4) · South Korea (4) · Hong Kong (3) · Taiwan (3)
Alex Adjei (1) · Andrew E Place, MD, PhD (1) · Array BioPharma (1) · Benjamin Weinberg, MD (1) · Birgit Geoerger, MD (1) · Camilo Fadul, MD (1) · David Mankoff, MD, PhD (1) · Giles W. Robinson, MD (1) · Jim Zhong (1) · John M Maris, MD (1) · Kari Wisinski, MD (1) · Lara E Davis (1) · Mariko D. DeWire-Schottmiller, MD (1)
PMID 36800111, PMID 42334791, PMID 29059492, PMID 30941307, PMID 31399936, PMID 31538815, PMID 32354716, PMID 32619077, PMID 32669376, PMID 32887722, PMID 33034839, PMID 33555033, PMID 33892407, PMID 34347542, PMID 34433648, PMID 34543871, PMID 35292802, PMID 35294522, PMID 36969745, PMID 37580773, PMID 38746220, PMID 39809926, PMID 41838385, PMID 42686334
2015 (2), 2023 (2), 2009 (1), 2014 (1), 2016 (1), P30CA138292 (1), UM1CA081457 (1)